Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast

Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast

NASDAQ, TSX: NVCN

VANCOUVER, March 21, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.

Conference Call & Webcast
Wednesday, March 28(th) @ 4:30pm Eastern Time

    Domestic:                           800-281-7973

    International:                      323-794-2093

    Passcode:                                                                        4395026

    Webcast:                            http://public.viavid.com/index.php?id=128910


    Replays available through April 10:

    Domestic:                           844-512-2921

    International:                      412-317-6671

    Conference ID:                                                                   4395026

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer(TM), for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara(TM), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568

SOURCE Neovasc Inc.